Stock Financial Ratios, Dividends, Split History

RGA / Reinsurance Group of America, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price138.13
Volume423,600.00
Market Cap ($M)8,865.47
Enterprise Value ($M)10,333.00
Book Value ($M)9,008.26
Book Value / Share139.61
Price / Book1.01
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 64,481,393
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 65,753,000
Weighted Average Number Diluted Shares Outstanding Adjustment 1,326,000
Common Stock Shares Outstanding 64,452,095
Weighted Average Number Of Shares Outstanding Basic 64,427,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.15
Return on Assets (ROA)0.03
Return on Equity (ROE)0.26
Balance Sheet (mrq) ($M)
Assets60,954.82
Liabilities51,946.56
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues12,515,769,000.00
Supplementary Insurance Information Premium Revenue9,841,130,000.00
Investment Revenue0.00
Net Income1,822.18
Earnings Per Share Basic28.28
Earnings Per Share Diluted27.71
Cash Flow Statement (mra) ($M)
Cash From Operations1,982.31
Cash from Investing-1,607.57
Cash from Financing-1,607.57
Identifiers and Descriptors
CUSIP759351604
Central Index Key (CIK)898174
Related CUSIPS
759351954 075935160 759351904
Industry Groups
SIC 6311 - Life Insurance

Split History

Stock splits are used by Reinsurance Group of America, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Avoid Reinsurance Group, Add These Top 4 Insurance Stocks

2018-06-20 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) has been witnessing southbound revisions of late. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 7.3% downward while for 2019, the consensus mark moved nearly 0.4% south. The stock carries a Zacks Rank #4 (Sell) with an unimpressive VGM Score of C. Back tested results show that stocks with a favorable VGM Score of A or B when combined with a bullish Zacks Rank #1 (Strong Buy) or 2 (Buy), comfortably outperform other stocks. (34-0)

Moving Average Crossover Alert: Reinsurance Group of America (RGA)

2018-06-19 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for RGA broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

Reinsurance Group Of America (RGA) Investor Presentation - Slideshow

2018-06-08 seekingalpha
The following slide deck was published by Reinsurance Group of America, Incorporated in conjunction with this event. (3-0)

Reinsurance Group Of America (RGA) Investor Presentation - Slideshow

2018-06-08 seekingalpha
The following slide deck was published by Reinsurance Group of America, Incorporated in conjunction with this event. (3-0)

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

2018-06-02 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (932-4)

CUSIP: 759351604